The U.S. Food and Drug Administration (FDA) is actively reworking how food allergens are regulated, moving away from simple ingredient disclosure toward a more risk-based system that could reshape food labeling and manufacturing practices. In February 2026, the agency held a series of public meetings and listening sessions to discuss food allergen thresholds, gluten cross-contact prevention, and how these concepts could affect labeling, manufacturing controls, and consumer safety.

What Is the FDA Actually Changing?

Right now, the FDA's allergen rules are relatively straightforward: food labels must identify nine major food allergens when used as ingredients, which include milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans, and sesame. The agency also addresses allergen cross-contact, which occurs when trace amounts of an allergen contaminate a food during manufacturing, through food safety requirements like current good manufacturing practices (cGMPs) and hazard analysis programs.

But here's the catch: the FDA does not currently require warning labels such as "may contain [allergen]" or "produced in a facility that also uses [allergen]" when cross-contact might occur. These statements are purely voluntary under current law, yet companies use them widely because of liability concerns. This creates a frustrating situation where some products are over-labeled with warnings while others lack them, leaving allergic consumers confused about which foods are truly safe.

The FDA's new direction signals a shift toward establishing allergen threshold levels, which would set specific concentration limits for how much of an allergen can be present before it poses a meaningful risk. This approach would be more expressly risk-based, emphasizing validated cross-contact controls and reference doses rather than relying solely on ingredient disclosure and voluntary warnings.

Why Are Allergen Thresholds So Important for Food Safety?

Nearly 1,800 people registered for the FDA's February 2026 listening sessions, with approximately 130 speakers participating, including industry representatives, consumer advocacy groups, academics, and healthcare professionals. The broad consensus among stakeholders was that a harmonized, risk-based threshold framework would help reduce inconsistent labeling, consumer confusion, and unnecessarily restricted food choices for people with allergies.

One key insight from the sessions: participants agreed that thresholds are most effective when applied to validate preventive controls, particularly sanitation and cleaning procedures on shared equipment, rather than relying on routine finished product testing. This makes sense because allergen cross-contact is non-uniform, and sampling can easily miss small particles or clumps. Participants also emphasized that any future threshold framework must translate clinical reference doses into practical concentration limits that manufacturers can actually implement and verify.

How to Prepare for Upcoming Allergen Labeling Changes

• Monitor FDA Guidance Updates: Food companies should stay informed about FDA's evolving allergen threshold work and gluten cross-contact initiatives, as binding compliance obligations may change in the coming months or years.
• Review Current Labeling Practices: Audit your product labels and advisory statements to ensure they accurately reflect your manufacturing processes and cross-contact risks, as future regulations may require substantiation of these claims.
• Strengthen Sanitation Controls: Invest in documented, validated cleaning procedures for shared equipment, as threshold-based frameworks will likely emphasize preventive controls over finished product testing.
• Engage with Supply Chain Partners: Work with ingredient suppliers and contract manufacturers to close data gaps about allergen presence and cross-contact risks throughout your supply chain.

The FDA's separate gluten initiative is also moving forward, seeking information on labeling and preventing cross-contact of gluten in packaged foods, with specific attention to rye, barley, and oats. At the state level, California's SB 68, which took effect July 1, 2026, requires covered food facilities to provide written notification of major food allergens in menu items. New York has also enacted allergen labeling requirements for certain prepackaged foods, effective November 2026.

In Congress, two bills reflect growing attention to allergen and food labeling transparency: H.R. 9048, the Celiac Safety Act of 2026, would amend federal law to include gluten-containing grains in the definition of "major food allergen," while H.R. 8385, the Food Labeling Modernization Act of 2026, addresses broader nutrient and front-of-package labeling.

For now, companies must still comply with existing binding obligations: major food allergen labeling requirements, truthful and non-misleading labels, and adequate cGMP and preventive control programs to prevent or significantly minimize allergen cross-contact. However, the practical reality is shifting. Allergen compliance may increasingly depend not just on what the label says, but on whether a company can substantiate the risk through validated controls and documented evidence. The plaintiffs' bar is already active in allergen and food labeling disputes, making this an area where regulatory change and litigation risk converge.

The bottom line: if you manufacture food products or have a food allergy, pay attention to these developments. The FDA's allergen framework is evolving from a simple ingredient-disclosure model toward a more sophisticated, risk-based system that will require stronger documentation, clearer communication, and more rigorous manufacturing controls.